DRMA Dermata Therapeutics, Inc. - Common Stock
$1.46
Price · Aug 19, 2026
52W Range
$1–$6
10% of range
Analyst Rating
BUY
7 analysts
Price Target
$4
+174% upside
P/E (TTM)
—
ROE
—
Net Profit Margin
—
DRMA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$1.46
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$1 – $6
DRMA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
DRMA
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
DRMA
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
DRMA
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
DRMA
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
DRMA
Peer Median
DRMA Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
7 analysts
- Strong Buy 2 28.6%
- Buy 4 57.1%
- Hold 1 14.3%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
1 analysts · 2026-08-17
Low
$4.00
High
$4.00
Median target
$4.00
+174.0%
Mean target
$4.00
+174.0%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-0.57%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| June 30, 2026 | $-0.74 | $-0.56 | -0.18% |
| March 31, 2026 | $-0.48 | $-0.54 | 0.06% |
| Dec. 31, 2025 | $-1.52 | $-1.57 | 0.05% |
| Sept. 30, 2025 | $-1.65 | $-1.62 | -0.03% |
| June 30, 2025 | $-1.66 | $-2.96 | 1.3% |
| March 31, 2025 | $-4.50 | $-4.59 | 0.09% |
| Dec. 31, 2024 | $-20.60 | $-15.30 | -5.3% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| DRMA | — | — | — | — | — | — |
| CDIO | — | — | — | — | — | — |
| ACXP | $6M | -0.5 | — | — | -180.3% | — |
| PMCB | $8M | -0.3 | — | — | -56.7% | — |
| BRTX | $10M | -0.7 | -10.3% | -3959.4% | -547.6% | 93.4% |
| XBIO | — | -1.4 | 19.0% | — | — | — |
| GOVX | $296.2K | — | -37.1% | -862.3% | -645.9% | — |
| LABT | — | — | — | — | — | — |
| BCAB | — | -0.6 | — | — | — | — |
| TCRT | — | -1.5 | -50.0% | — | — | — |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 13 filers · $150K total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 7 (+3 vs prior Q) | 1 (-3 vs prior Q) | 1 (0 vs prior Q) | 2 (+1 vs prior Q) | +34K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | $26,061 | 20,203 | 17.43% | Shares |
| Welch & Forbes LLC | $25,800 | 20,000 | 17.25% | Shares |
| STATE STREET CORP | $24,184 | 18,747 | 16.17% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $20,626 | 15,989 | 13.79% | Shares |
| XTX Topco Ltd | $19,075 | 14,787 | 12.76% | Shares |
| UBS Group AG | $13,148 | 10,192 | 8.79% | Shares |
| Advisory Alpha, LLC | $12,900 | 10,000 | 8.63% | Shares |
| Tower Research Capital LLC (TRC) | $4,979 | 3,860 | 3.33% | Shares |
| MCF Advisors LLC | $2,235 | 1,732 | 1.49% | Shares |
| BARCLAYS PLC | $348 | 270 | 0.23% | Shares |
| SBI Securities Co., Ltd. | $130 | 101 | 0.09% | Shares |
| HIGHLINE WEALTH PARTNERS LLC | $34 | 26 | 0.02% | Shares |
| MORGAN STANLEY | $3 | 2 | 0.00% | Shares |
Company insiders 13 insiders · 5 officers · 8 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| PROEHL GERALD T | President, CEO and Chairman | Jan. 3, 2022 A | 59,512 | 0 | 0 | $0 |
| Kyri K. Van Hoose | SVP, Chief Financial Officer | Jan. 3, 2022 A | — | 0 | 0 | $0 |
| Thomas Insley | Chief Financial Officer | Aug. 17, 2021 C | 14,337 | 0 | 0 | $0 |
| Christopher J. Nardo | Senior VP, Development | Jan. 3, 2022 A | 2,439 | 0 | 0 | $0 |
| Munera Maria E Bedoya-Toro | Senior Vice President | Jan. 3, 2022 A | 84,143 | 0 | 0 | $0 |
| Brittany Bradrick | Director | April 7, 2022 A | 5,031 | 0 | 0 | $0 |
| Kathleen D. Scott | Director | April 7, 2022 A | 5,826 | 0 | 0 | $0 |
| Andrew Seth Sandler | Director | April 7, 2022 A | 5,190 | 0 | 0 | $0 |
| Mary Fisher | Director | April 7, 2022 A | 5,031 | 0 | 0 | $0 |
| Wendell Wierenga | Director | April 7, 2022 A | 15,471 | 0 | 0 | $0 |
| HALE DAVID F | Director | April 7, 2022 A | 19,124 | 0 | 0 | $0 |
| Steven J Mento | Director | Jan. 3, 2022 A | — | 0 | 0 | $0 |
| Proehl Investment Ventures LLC | 10% owner | Aug. 17, 2021 C | 2,905,544 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 4 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Kyri K. Van Hoose | June 1, 2026 | 9.00% | Initial filing | Passive investment | SEC |
| PROEHL GERALD T ×7 filings | Feb. 23, 2026 | 17.30% | Amendment | — | SEC |
| David Hale, Hale BioPharma Ventures LLC ×2 filings | March 31, 2023 | — | Initial filing | — | SEC |
| Gerald T. Proehl, Proehl Investment Ventures LLC ×4 filings | March 30, 2023 | — | Initial filing | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.